Novavax’s Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU

GAITHERSBURG, Md., Oct. 9, 2024 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the European Commission granted Marketing Authorization for Novavax’s updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in individuals aged 12 and older for the prevention of COVID-19 in the European Union (EU). This decision follows the positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA).

Authorization was based on non-clinical data that showed Novavax’s updated vaccine provides cross-reactivity against JN.1 and numerous JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1.1 In clinical trials, the most common adverse reactions associated with Novavax’s prototype COVID-19 vaccine (NVX-CoV2373) included headache, nausea or vomiting, muscle pain, joint pain, injection site tenderness, injection site pain, fatigue and malaise.

Novavax’s vaccine is also authorized for use in the U.S., and is in line with guidance from the U.S. Food and Drug Administration (FDA), EMA and the World Health Organization to target the JN.1 lineage this fall.2-5

AUTHORIZED USE IN THE U.S.
Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) has not been approved or licensed by the FDA but has been authorized for emergency use by the FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older. Refer to the full Fact Sheet for information about the Novavax COVID-19 Vaccine, Adjuvanted.

The EUA of this product will remain in effect for the duration of the COVID-19 EUA declaration justifying emergency use of the product, unless the authorization is revoked sooner.

VACCINE AUTHORIZATION (U.S.)
Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.

IMPORTANT SAFETY INFORMATION
Contraindications

  • Do not administer the Novavax COVID-19 Vaccine, Adjuvanted to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Novavax COVID-19 Vaccine, Adjuvanted.

Warnings and Precautions

  • Management of Acute Allergic Reactions: Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of the Novavax COVID-19 Vaccine, Adjuvanted.
  • Myocarditis and Pericarditis: Clinical trials data provide evidence for increased risks of myocarditis and pericarditis following administration of Novavax COVID-19 Vaccine, Adjuvanted.
  • Syncope (fainting): may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.
  • Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Novavax COVID-19 Vaccine, Adjuvanted.
  • Limitations of Vaccine Effectiveness: The Novavax COVID-19 Vaccine, Adjuvanted may not protect all vaccine recipients.

Adverse Reactions
Solicited adverse reactions included: Injection site pain/tenderness, fatigue/malaise, muscle pain, headache, joint pain, nausea/vomiting, injection site redness, injection site swelling and fever.

Reporting Adverse Events and Vaccine Administration Errors

The vaccination provider is responsible for mandatory reporting of certain adverse events to the Vaccine Adverse Event Reporting System (VAERS) online at https://vaers.hhs.gov/reportevent.html, by calling 1-800-822-7967 or send an email to [email protected].

About the Novavax COVID-19 2024-2025 Formula (NVX-CoV2705)
NVX-CoV2705 is an updated version of Novavax’s prototype COVID-19 vaccine formulated to target the JN.1 variant. It is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID-19. With Novavax’s unique recombinant nanoparticle technology, the non-infectious spike protein serves as the antigen that primes the immune system to recognize the virus, while Novavax’s Matrix-M adjuvant enhances and broadens the immune response. The vaccine is packaged as a ready-to-use liquid formulation and is stored at 2° to 8°C, enabling the use of existing vaccine supply and cold chain channels.

About Matrix-M™ Adjuvant
When added to vaccines, Novavax’s patented saponin-based Matrix-M adjuvant enhances the immune system response, making it broader and more durable.3 The Matrix-M adjuvant stimulates the entry of antigen-presenting cells at the injection site and enhances antigen presentation in local lymph nodes.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax’s patented Matrix-M adjuvant to enhance the immune response. The Company’s portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax’s adjuvant is included in the University of Oxford and Serum Institute of India’s R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and prospects, the immunogenic response of its vaccine technology against variant strains including JN.1 lineage viruses, and the scope, timing and outcome of future regulatory filings and actions, including any EMA or FDA recommendations, the expectation to have unit dose vials available in select European countries this fall season, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, antigenic drift or shift in the SARS-CoV-2 spike protein, challenges satisfying, alone or together with partners, various safety, efficacy and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges or delays in obtaining regulatory authorization for a JN.1 protein-based COVID-19 vaccine or for future COVID-19 variant strain changes; challenges or delays in clinical trials; manufacturing, distribution or export delays or challenges; Novavax’s exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the impact of any delays or disruptions in their operations on the delivery of customer orders; and those other risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Novavax’s Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:
Investors
Luis Sanay, CFA
240-268-2022
[email protected]

Media
Giovanna Chandler
240-720-7804
[email protected]

References

  1. Kaku Y, Uriu K, Okumura K; Genotype to Phenotype Japan (G2P-Japan) Consortium, Ito J, Sato K. Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant. Lancet Infect Dis. 2024;24(10):e609. doi:10.1016/S1473-3099(24)00505-X
  2. U.S. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States. September 6, 2024. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.
  3. U.S. Centers for Disease Control and Prevention. CDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines for Fall/Winter Virus Season. June 27, 2024. Available at: https://www.cdc.gov/media/releases/2024/s-t0627-vaccine-recommendations.html.
  4. World Health Organization. Statement on the antigen composition of COVID-19 vaccines. April 26, 2024. Available at: https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines.
  5. European Medicines Agency. ETF recommends updating COVID-19 vaccines to target new JN.1 variant. April 30, 2024. Available at: https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19-vaccines-target-new-jn1-variant.

 

Novavax logo (PRNewsfoto/NOVAVAX, INC)

 

SOURCE Novavax, Inc.

Source link

Visited 1 times, 1 visit(s) today

Related Article

Local cardiology practice among 16 paying $17M for allegedly violating False Claims Act

BOWLING GREEN, Ky. – A total of 16 cardiology practices have agreed to pay a total of nearly $17.7 million to resolve allegations that they each violated the False Claims Act, including a practice in Warren County. The United States Attorney’s Office, Western District of Kentucky provided a release Friday stating the government alleges that

Another pandemic is inevitable, and we’re not ready

F.D. Flam Every week or so, scientists issue another warning that the H5N1 bird flu is inching closer to exploding into a pandemic. Despite having contended with a pandemic that broke out less than five years ago, the U.S. has no solid plan to handle a new one — nor have our leaders done anything to incorporate

Louisiana forbids public health workers from promoting COVID, flu and mpox shots : Shots

Physician assistant Danis Walker vaccinates a construction worker outside a Lowes Home Improvement store in New Orleans on June 11, 2021. Rosemary Westwood/WWNO hide caption toggle caption Rosemary Westwood/WWNO A group of high-level managers at the Louisiana Department of Health walked into a Nov. 14 meeting in Baton Rouge expecting to talk about outreach and

The Coronavirus Test Kits Market: Trends, Growth, and Outlook

Coronavirus Test Kits Market The global outbreak of the coronavirus (COVID-19) pandemic catalyzed unprecedented demand for diagnostic tools, thrusting the coronavirus test kits market into the spotlight. As countries scrambled to curb the spread of the virus, the development, production, and deployment of test kits became a global priority. This article delves into the dynamics

Fauci was told by Feb. 2020 that COVID was already ‘adapted’ to humans

U.S. and Chinese government officials knew as early as February 2020 that the emerging novel coronavirus that causes COVID-19 had already been well-adapted to humans – an early signal not only that it would spread efficiently, but also that it may not have emerged at the Wuhan wet market. Recently released chat messages indicate that

Three questions on “The Missed Opportunity for Reform in the Wake of COVID-19”

This conversation is with the authors of the chapter “Everything Is Different but Nothing Is New: The Missed Opportunity for Reform in the Wake of COVID-19” in our new co-edited book, Recentering Learning: Complexity, Resilience, and Adaptability in Higher Education (JHU Press, 2024). The book (in paper and ebook form) is available for order from

What is health equity and how can it help achieve universal health coverage?

    Universal Health Coverage (UHC) means everyone can access healthcare without financial hardship, but progress towards achieving this has stalled. The latest research on achieving UHC also focuses on the need for health equity, which is when everyone can attain their full health and wellbeing potential. This will require a willingness by healthcare leaders

Moderna | History, Innovation, Challenges, & Facts

Moderna uses mRNA technology to combat COVID-19, RSV, cancer, and rare diseases. © Plexi Images/GHI/UCG—Universal Images Group/Getty Images Share price: $38.36 (mkt close, Dec. 18, 2024) Annual revenue: $5.08 bil. Earnings per share (prev. year): $-5.81 Moderna, Inc. is a biotechnology company specializing in messenger RNA (mRNA) medicines and is best known for developing one

American lifespans increased in 2023

Average life expectancy in the U.S. increased by almost a year in 2023, rebounding to a level not reached since the COVID-19 pandemic, according to figures released Thursday by the Centers for Disease Control and Prevention. U.S. average life expectancy was 78.4 years in 2023 ‒ nearly 11 months longer than in 2022 ‒ mostly

New long COVID index highlights five symptom subtypes

RECOVER-Adult study reveals refined thresholds and symptom categorization, advancing research into long COVID’s complexities. Study: 2024 Update of the RECOVER-Adult Long COVID Research Index. Image Credit: Branislav Nenin / Shutterstock.com The 2023 research index for adults with post-coronavirus disease 2019 (COVID-19) condition or long COVID has been updated using additional participant data from the Researching COVID

How Many People Have Died from COVID-19? A Look at the Virus Four Years Later

What’s New Deaths from COVID-19 have slowed significantly but continue adding to a tally of more than 7 million deaths from the virus in the nearly five years since the World Health Organization (WHO) declared a pandemic. Why It Matters The world was transformed by the emergence of SARS-CoV-2, the coronavirus that causes COVID-19. Business

COVID-19 And RSV Present In Los Alamos County Wastewater – Los Alamos Reporter

COUNTY NEWS RELEASE Recent data from the CDC National Wastewater Surveillance System indicates very high COVID-19 activity in New Mexico, based on wastewater samples collected from Santa Fe and Bernalillo counties between December 1 and December 7. In Los Alamos County, BioBot Analytics data shows COVID-19 concentrations in the Los Alamos townsite wastewater decreased from 10 million copies per liter

Data: COVID-19 activity is high in New Mexico

ALBUQUERQUE, N.M. — Data from the Centers for Disease Control and Prevention and the New Mexico Department of Health is showing high COVID-19 activity in our state. The CDC tests wastewater to detect traces of several infectious diseases, including COVID. According to data from wastewater sites in Bernalillo County and Santa Fe, which serve 650,000

Novavax is as protective as other Covid vaccines, but has fewer side effects

The first time I got a Novavax Covid vaccine, it felt almost subversive. Over the previous few years, every mRNA-based booster I’d gotten — the ones made by Moderna and Pfizer — had felt like a two-day bout of the flu. I’d gamely booked sick days into my calendar and sucked it up through fevers,

Long COVID affects 8.4% of U.S. adults, with income and geography shaping impact

Millions of Americans struggle with long COVID, as new data reveals how income, geography, and gender amplify its debilitating effects. Research Letter: Prevalence of Post–COVID-19 Condition and Activity-Limiting Post–COVID-19 Condition Among Adults. Image Credit: p.ill.i / Shutterstock In a recent study published in JAMA Network Open, researchers from the Centers for Disease Control and Prevention explored the

Hydroxychloroquine study retracted; drug isn’t treatment for COVID

A discredited study that set off a flurry of interest in using an antimalarial drug to treat COVID-19 has now been formally withdrawn. A scientific journal on Tuesday retracted the March 2020 study that introduced the world to hydroxychloroquine early in the COVID-19 pandemic – and confirmed that the attention was undeserved from the start.

COVID: Updated CDC Map Reveals Infection Rates Across US

Coronavirus infections in the United States are up in December, according to the latest figures from the Centers for Disease Control and Prevention (CDC). The week that ended Saturday, December 7, saw test positivity rates rise to 5.4 percent; higher than the last week of November (4 percent) and the week before (4.5 percent). Rates

5 Things to Know About COVID-19 Before the Holiday Season

The holidays come each year and often bring with them seasonal sickness, whether it’s driven by seeing family for the holiday, traveling, or the cold weather. COVID-19 remains a prevalent health issue in the US, with the rate of COVID-19 hospitalizations reaching 16.5 per 100,000 persons in the current 2024-2025 season.1 With this number expected

0
Would love your thoughts, please comment.x
()
x